In view of the probably mutation-independent and sharp upregulation of IGF2BP1 in ATC, as well as its frequently reported expression in other aggressive cancers [14, 38], our study strongly suggests expediting the clinical evaluation and also improvement of IGF2BP1-directed inhibitors in cancer therapy. The gene discussed is IGF2BP1; the disease is cancer.